Phio Pharmaceuticals (PHIO) Other Operating Expenses (2012 - 2023)
Phio Pharmaceuticals' (PHIO) quarterly Other Operating Expenses came in at $126000.0 in Q4 2023, up 48.24% quarter-over-quarter from $85000.0 in Q2 2017.
Powered by 
Analysis
Phio Pharmaceuticals (PHIO) Other Operating Expenses (2012 - 2023) Analysis & Trends
Phio Pharmaceuticals (PHIO) has reported Other Operating Expenses for 4 consecutive years, with $126000.0 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Other Operating Expenses changed N/A year-over-year to $126000.0; the trailing twelve-month figure through Sep 2024 stood at $126000.0 (changed N/A YoY), and the FY2023 full-year result was $126000.0, changed N/A from the prior year.
- Other Operating Expenses grew to $126000.0 in Q4 2023 per PHIO's latest filing, from $85000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $126000.0 in Q4 2023 and bottomed at $126000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Phio Pharmaceuticals | 12.55 Mn | 12.55 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 126,000.00 |
| Jun 30, 2017 | 85,000.00 |
| Mar 31, 2017 | 4.61 Mn |
| Mar 31, 2013 | -473,000.00 |
| Dec 31, 2012 | -650,000.00 |
| Sep 30, 2012 | -387,000.00 |
| Mar 31, 2012 | -674,000.00 |